ABSTRACT
Optimal management of prostate cancer remains elusive. At every stage on the patient pathway from diagnosis, localization, staging, and treatment planning to follow-up, there is a need to maximize information. This would allow better decision-making for both clinician and patient as, given the heterogeneous nature of prostate cancer, radical treatment and its associated sequelae must be balanced against active surveillance. In this chapter, we will discuss how magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) can help in this decision-making. At present, the American Urological Association recommends that MRI be performed when the prostatespecific antigen (PSA) is over 25 ng/mL.1 We aim to show, however, that, with recent developments, magnetic imaging should be undertaken more often than currently recommended.
